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Background: Clinical phenotype varies among cystic fibrosis (CF) patients with identical CF transmembrane conductance regulator (CFTR)
genotype, suggesting that genetic modifiers exist. Transgenic mice that overexpress SCNN1β present CF-like lung disease symptoms.
Mutations or variants in SCNN1β may therefore potentially modulate the clinical phenotype in CF patients.
Methods: We analysed by DHPLC SCNN1β and SCNN1γ genes in 56 patients with classical CF. Patients were classified into two groups
according to their CFTR genotype and their severity: 38 patients with severe genotype and an unexpectedly mild lung phenotype, and 18
patients with mild genotype and a severe lung phenotype.
Results: We found 3 patients out of 56 carrying at least one missense mutation. Two were novel (p.Thr313Met in SCNN1β, p.Leu481Gln in
SCNN1γ) and two were previously described (p.Gly589Ser in SCNN1β and p.Val546Ileu in SCNNγ). p.Thr313Met has been identified in a
CF patient with mild genotype and severe lung phenotype suggesting that it could act in increasing ENaC activity. The three other variants
have been identified in CF patients with severe genotype and mild lung phenotype suggesting that they might decrease ENaC activity.
However, the function of ENaC in the nasal epithelia of these patients, evaluated by nasal potential difference measurements, did not support
the fact that these variants were functional, at least in nasal epithelium.
Conclusion: Our results suggest that genetic variants in ENaCβ and γ genes do not modulate disease severity in the majority of CF patients.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: ENaC; CFTR; Cystic fibrosis1. Introduction
Cystic fibrosis (CF) is an autosomal recessive disorder that
affects chloride and sodium transport in various epithelia,
including the sweat gland, respiratory tract, pancreas, and
male reproductive system. Linkage positional cloning
identified the CFTR gene encoding, a cAMP-activated
chloride channel as responsible for CF. More than 1300⁎ Corresponding author. Laboratoire de Biochimie et Génétique Molécu-
laires, CHU Cochin, 123 boulevard de Port Royal, 75014, Paris, France.
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1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2007.04.003disease-associated mutations have been reported in CFTR,
and onemutation, Phe508del (also named F508del), accounts
for approximately 70% of alleles worldwide. Disease severity
and complications vary considerably among affected organ
systems. For some tissues, such as the exocrine pancreas,
severity is closely correlated with CFTR genotype. However,
the CFTR genotype is poorly correlated with the severity of
lung disease and with the occurrence of numerous complica-
tions. Therefore, the contribution of factors independent of
theCFTR genotype to disease outcome depends on the tissue/
organ system. Previous twin and sibling studies suggest that
severity of lung disease is determined by interactions between
the CFTR genotype and factors shared between twins and
siblings such as modifier genes and/or environmentaled by Elsevier B.V. All rights reserved.
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genetic polymorphisms act asmodifiers of lung disease in CF,
but only genetic variation in the 5′ end of TGFβ1 (Trans-
forming growth factor-β1) or nearly upstream region appears
to modify disease severity in cystic fibrosis in replication
studies [2].
The pathogenesis of CF lung disease reflects a defect in the
innate defense of airway surfaces against bacterial infection.
Numerous mechanisms have been proposed to link the defect
in CFTR expression or function to CF airway disease. In the
early to mid-1990s, two major hypotheses have emerged that
focused on the role of superficial epithelia in regulating the
protective properties of the thin film of liquid that lines
airway surfaces. The compositional hypothesis emphasized
the function of CFTR as a Cl– channel to produce a low-salt
airway surface liquid (ASL) that activates antimicrobial
peptides. In CF, CFTR dysfunction would result in high-salt
ASL, which would inactivate the antimicrobial peptides and
result in chronic infection [3]. The other hypothesis, the low-
volume hypothesis, emphasized the role of CFTR as both a
Cl– channel and a regulator of the epithelial sodium channel
ENaC, to optimize ASL volume and promote effective
mechanical clearance of the lung. In CF, the absence of these
CFTR functions was predicted to result in increased Na+ and
water absorption, depletion of ASL volume, impaired me-
chanical clearance of mucus, and infection [4]. Although
there have been many studies designed to explore the relative
merits of each hypothesis, the most relevant approach was to
test the ionic composition of normal ASL. Virtually all of the
recent in vivo data have allowed a consensus to be reached in
showing that the ASL is not only isotonic with plasma but is
also not different in normal versus CF patients [5]. Similar
conclusions were drawn from studies in normal and CF mice.
Thus, it appears that the weight of evidence would favour an
isotonic liquid on airway surfaces, which strongly favours the
low volume hypothesis.
The amiloride-sensitive epithelial sodium channel (ENaC)
is expressed in specific tissues (such as the distal colon, the
distal part of the renal tubule, respiratory airways, and in the
duct of several exocrine glands, such as salivary and sweat
glands) and functions in the transport of sodium across
epithelial cells from the lumen into the epithelial cell. Func-
tional ENaC is composed of four subunits, two alpha subunits
separated by beta and gamma subunits [6]. Each ENaC
subunit activity may be regulated by interacting with other
proteins like CFTR [7]. In humans, mutations in ENaC
subunits have been shown to cause a multi-system form of
pseudohypoaldosteronism (PHA) type I, which is a salt-
wasting disease [8], and Liddle's syndrome which is charac-
terized by hereditary hypertension [9]. These two diseases
respectively result from either the loss of function of ENaC
or excess activity of ENaC. Interestingly, besides the usual
symptoms of salt wasting, PHA patients also frequently ex-
hibit respiratory tract disease, especially up to the age of 5–6
years [10]. Moreover, an excess of airway surface liquid
was reported that was due to inadequate absorption of sodiumand water because of defective ENaC function [11]. In
mouse, inactivation of the genes coding for alpha, beta or
gamma ENaC has clearly demonstrated that all three ENaC
subunits are essential for survival. These modifications led to
reduced or even abolished ENaC activity [12]. Mice deficient
for the ENaCa gene locus present poor feeding, costral retrac-
tions, and cyanosis a few hours after birth, and die with their
lungs filled with fluid. Mice deficient for either ENaCb or
ENaCg show delayed lung liquid clearance at birth, but
otherwise do not exhibit the symptoms of respiratory distress
like ENaCa– mice. Mice deficient in Cftr (Cftr–) develop a
range of intestinal pathology that may cause fatal complica-
tions after bowel obstruction at birth or when weaned to solid
chow. However, these Cftr– mice do not develop a
spontaneous CF-like lung disease, although it was soon
discovered that lung disease could be induced by exposure to
high levels of bacteria [13; 14; 15]. In contrast to Cftr– mice,
overexpression of ENACb (also named Scnn1b) (but not
Scnn1a or Scnn1c) inmice was sufficient to cause a significant
increase in sodium absorption, and to produce a severe
spontaneous lung disease sharing key features with CF in
humans [16]. These data suggest that increased sodium
absorption was the initiating event in the pathogenesis of
CF-like lung disease in ENaC transgenic mice. The data from
studies of ENaCb overexpressing mice may also provide
insights into the absence of a pulmonary disease phenotype in
Cftr– mice. Mice normally express Cftr predominatly in the
upper airways and not in the lower airways. ENaC is regulated
by Cftr in the nose and other regulatory mechanisms exist in
the lower airways. Sodium hyperabsorption is observed in the
Cftr– mouse nasal cavity and, indeed, there is an associated
phenotype of goblet cell hyperplasia. In contrast, there is no
elevation of sodium transport in Cftr– mouse lower airways
and, in parallel, no pathology.
The cystic fibrosis-like lung disease in ENaC transgenic
mice and the well known interaction between CFTR and
ENaC led to the hypothesis that variants (or “mild” ENaC
mutations) in ENaC subunit sequences may be responsible
for pulmonary heterogeneity in CF patients, even among the
patients carrying identical CF gene mutations [16]. Recently,
sequencing of the exons and flanking introns of the genes
encoding the α, β, and γ subunits of ENaC in 20 non-classic
CF patients without CFTRmutations identified five missense
mutations (one in ENaC α and four in ENaCβ) and one
splicing mutation in the 3′ splice site of ENaCβ intron
12 [17].
To further our understanding of the role of ENaC in the
development of the CF phenotype, we extensively analysed
ENaCβ and ENaCγ genes in 56 adult patients with CF and
discordance between the clinical respiratory phenotype and
the CFTR genotype. To limit the influence of environmental
factors including medical care practice, we chose to study
only the adult CF patients who regularly attended the adult
CF centre at Cochin Hospital, Paris, France. Patients were
classified into two genotype groups according to the pro-
bable effect of their mutations on CFTR function, regardless
Table 1
Parameters for amplification of the ENaCβ and ENaCγ gene fragments
(GenBank accession number NM_000336 and NM_001039, respectively)
Fragment Sequence of primers Annealing
temperature (°C)
ENaCβ
Exon 2 2F 5′ gtgtcccagctgatgtgcgt 3′ 55
2R 5′ tgaggccagctgtgcactcc 3′
Exon 3 3F 5′ acagactactatggagtggg 3′ 55
3R 5′ aagaaacacccatcagcctc 3′
Exon 4 4F 5′ gtcctgctagcagctcccac 3′ 59
4R 5′ caaccgtaacatgccactgt 3′
Exon 5 5F 5′ ctgccctgcagctgatgctg 3′ 55
5R 5′ ccctgcaacagctgatggtc 3′
Exon 6 6F gtctcctttctgcctcagga 3′ 59
6R 5′ tcagaccctctaggactgcc 3′
Exon 7 7F 5′ aggtgcagaaagggcttcct 3′ 63
7R 5′ catgaggcgtgcaccaccttcccac 3′
Exon 8 8F 5′ ctgaccatgcctgtgttctc 3′ 59
8R 5′ ctctatggtcagagcctctg 3′
Exon 9–10 9F 5′ cagaggctcagcagggaaca 3′ 63
10R 5′ catcttatgcccagacttgt 3′
Exon 11 11F 5′ gatgctgcagatggcaactt 3′ 55
11R 5′ gagctgtcctgtgtccaaac 3′
Exon 12 12F 5′ acattagtcccggcccttct 3′ 55
12R 5′ ggtattgggagactcctaaa 3′
Exon 13 13F 5′ fgaggcaagaatgtgtggcct 3′ 59
13R 5′ tcttggctgctcagtgagtt 3′
ENaCγ
Exon 2 2F 5′ agcacgcccgtcctcagagt 3′ 57
2R 5′ ccagtgtgtcactttcggga 3′
Exon 3 3F 5′ tgaggctgacacgtgttgat 3′ 55
3R 5′ tgcccctaagcagtgaaaga 3′
Exon 4 4F 5′ agtagcgataggaccgatgg 3′ 55
4R 5′ tcagagctgccagtccttag 3′
Exon 5 5F 5′ cccaacttcagctaagatgc 3′ 55
5R 5′ agatctccttggcacaggtt 3′
Exon 6 6F 5′ ttggatcacagcaggttgtc 3′ 55
6R 5′ gatctgttctctccaagcct 3′
Exon 7 7F 5′ ctgtctggtgctccttgcaa 3′ 55
7R 5′ ccagcttagatataactttg 3′
Exon 8 8F 5′ tgagcaaagacatgaatggc 3′ 57
8R 5′ agtgcctattgccaggacta 3′
Exon 9–10–11 9F 5′ tccaaagctcatgctgccct 3′ 57
11R 5′ acagaggaacagggtagagg 3′
Exon 12 12F 5′ ggatgccaaggctcttgatt 3′ 52
12R 5′ gccaggaagatgctcacatt 3′
Exon 13 13F 5′ aggttcctcttgatggtgt 3′ 55
13R 5′ ggtcctgactagatctgtct 3′
Table 2
Parameters for dHPLC conditions
Fragment Temperature (°C)
ENaCβ
Exon 2 62.3/63.3
Exon 3 59.5/60.7
Exon 4 62.2/63.4
Exon 5 59.5/61
Exon 6 63
Exon 7 61.6/62.6/63.6
Exon 8 62.8/64.8
Exon 9–10 61.5/62.5/65
Exon 11 61/62/63.5
Exon 12 69
Exon 13 61/63.3/64.8
ENaCγ
Exon 2 60.8/63.2/66
Exon 3 61/61.4
Exon 4 60.6
Exon 5 59.5/60.5
Exon 6 56.5/59/60.5
Exon 7 63/63.6
Exon 8 59.5/63
Exon 9–10–11 60.7/61.5/62.7/64.7
Exon 12 59.5/61.7
Exon 13 61/62.2
25M. Viel et al. / Journal of Cystic Fibrosis 7 (2008) 23–29of clinical features, using the classification of CFTR
mutations proposed by Welsh and Smith and expanded by
Zielenski and Tsui [18,19]. We only tested patients who were
homozygous for the p.Phe508del mutation or compound
heterozygous for two severe mutations (class I, II and III)
and had an unexpectedly mild lung phenotype based on
FEV1 criteria and age, and patients who were compound
heterozygous for at least one mild mutation (class IV and V)
and had a severe lung phenotype, on the basis of the
hypothesis that adverse and beneficial genetic variants would
be enriched, respectively, in these two groups of disease
severity.2. Materials and Methods
2.1. Patients
All patients were recruited from the CRCM (adult CF
centre) of Cochin University Hospital, Paris, France, where
they benefit from homogeneous therapeutic management and
longitudinal follow-up of their respiratory function. Diag-
nosis of CF was made according to the 1998 international
consensus statement [20]. Information on gender, CFTR
genotype, pancreatic status, forced expiratory volume in one
second (FEV1) expressed as the percentage of the predicted
value and body mass index (BMI) (weight/height2), was
collected. Complete information was obtained for all patients.
FEV1 was chosen because it is the variable that best reflects
the status of lung function throughout the course of CF lung
disease, and the cut off points of 30% and 60% of the
predicted value were chosen to define severe or mild
respiratory insufficiency. We only included in this study CF
patients that had been selected for their extreme clinical
phenotype regarding their genotype.
The first group consisted of 38 CF patients with two severe
mutations (class I, II and III) and a mild lung disease defined
by a FEV1 higher than 60% predicted and/or an age over 40
years. Twenty-one were homozygous for the Phe508del
mutation and 17 were compound heterozygous or homo-
zygous for two severe mutations (R553X:1717-1GNA,
Phe508del:W1282X, Phe508del:1717-1GNA, 2 Phe508-
del:3659delC, Phe508del:N1303K, Phe508del:W57X,
Phe508del:Q1411X, G542X:1380insT, Phe508del:R553X,
26 M. Viel et al. / Journal of Cystic Fibrosis 7 (2008) 23–29Phe508del:I507del, Phe508del:4382delA, S549R:3120+
1GNA, Phe508del:3120+1GNA, Y122X:Y122X; Phe508-
del:W846X; Phe508del:E60X).
The second group consisted of 18 CF patients with at least
one mild mutation (mild genotype) and a severe respiratory
phenotype defined by a FEV1 lower than 30% predicted and/
or death or lung transplantation before the age of 40 years.
Their genotypes were: 2 G542X:3849+10kbCNT, Phe508-
del:3276-26ANG, Phe508del:A455E, 297-3CNT:W361R,
S1251N:3849+10kbCNT, Phe508del:G178R, Phe508-
del:3849+10kbCNT, Phe508del:A561E, Phe508del:
G1061R, 1717-1GNA:3272-26ANG, 2 Phe508del:R347P,
Phe508del:G85E, L227R:L227R, R300G:3007delG,
Phe508del:R347H, Phe508del:G1244E.
2.2. Methods
Genomic DNA was extracted from peripheral blood
lymphocytes according to standard protocols and was used
to amplify the thirteen exons (twelve coding exons; exon 2 to
exon 13) and the flanking sequences of the ENaCβ and
ENaCγ genes. All samples were collected after obtaining
informed consent.
The coding regions of ENaCβ and ENaCγ have been
amplified in 12 fragments. Primer sequences are described in
Table 1. Reactions were performed in a volume of 50 μl
containing 50 mM Tris–HCl (pH 8.4), 1.5 mM MgCL2,
200 μM of all four deoxynucleotides, 0.5 mM each of the
primers, 2.5 units of Taq Polymerase (Gold, Perkin Elmer)
and 100 ng template DNA. Forty cycles were then performed
with denaturation for 30 s at 72 °C. The DNA synthesis step
of the final cycle was extended to 7 min. For DHPLC
analysis, the amplified DNAwas heated at 94 °C for 7 min,
and at 55 °C for 4 min to favour formation of heteroduplexes.
Mutation analysis of the CF patients was performed by using
DHPLC (Wave DNA fragment analysis system, DNAsep
column; Transgenomics). DHPLC conditions were chosen
according to the Wavemaker program (Transgenomics, Santa
Clara, CA, USA) (Table 2). PCR products were subjected to
chromatography using appropriate temperatures and acetoni-
trile gradient at a flow rate of 0.9 ml/mn, and those showing
an abnormal DHPLC profile were directly sequenced on an
automated sequencer (ABI 3100, Applied Biosystems, USA)
using the BigDye Terminator method.
ESEs are target sequences for the family of conserved
essential splicing factors-the serine- and arginine-rich (SR)
proteins. ESEs play an important role in exon recognition.Table 3
Clinical data from CF patients bearing a missense mutation in ENaCβ or ENaCγ
Patient
number
CFTR
mutations
ENaC
mutations
Age,
years
Pancreatic
status⁎
1 F508del: F508del p.G589S 36 PI
2 F508del: F508del p.L481Q: p.V546IL 24 PI
3 F508del: R347P p.T313M 27 PS
PI: pancreatic insufficient, PS: pancreatic sufficient, FEV1: forced expiratory flowNucleotide substitutions in ESEs lead in failure of SR proteins
to bind to the ESEs and to failure of splisosome machinery to
recognize the sequence as exonic, causing exon skipping
[21,22]. ESE motifs for four members of the SR family (SF2/
ASF, Srp40, Srp55, and SC35) have been identified. The
influence of base substitutions on putative ESE sites was
determined with the ESEfinder program (http://rulai.cshl.org).
The function of ENaC in the nasal epithelium was
evaluated by nasal potential (PD) difference measurement
as previously described [23]. The following measurements
were recorded: (1) the stable maximal baseline PD, which is
an estimate of the rate of Na+ transport; (2) the response to
superfusion with 10−4 M amiloride, a blocker of ENaC
(Δamil); (3) the change in PD following a perfusion of a low
chloride solution (Δ0Cl−/amil) to allow the determination of
basal chloride conductance (in this solution the chloride
contained in the amiloride solution was replaced by
gluconate), and (4) the response to the beta adrenergic
agonist isoproterenol (10−5 M) (Δiso/0Cl−) which was added
to the low chloride solution containing amiloride. Isoproter-
enol induces cAMP dependent chloride conductance and
determines the presence of CFTR. Superfusion of the nasal
epithelium with each solution was continued until a steady
state was reached, or for at least 3 min.
2.3. Statistics
The Hardy–Weinberg equation tested allelic disequili-
brium for the common polymorphisms. Comparison
between subjects grouped on the basis of their genotype
was accomplished by Fisher's exact test (two-tailed) for
categorical variables and by Mann–Whitney U test for
continuous variables. P values below 0.05 were defined as
significant.
3. Results
The human ENaCβ and ENaCγ genes are composed of
13 exons and encode a 640 and 649 amino acid protein,
respectively. The ATG start codon is located in exon 2 and
the TGA stop codon is located in exon 13. All the exons and
exon–intron junctions of the ENaCβ and ENaCγ gene were
screened for mutations and/or polymorphisms by dHPLC in
56 CF patients. DHPLC analysis revealed the absence of
mutations or polymorphisms in exons 3, 7, 8, 9, and 10 of the
ENaCβ gene and in exons 2, 5, 6, 7, 8 and 10 of the ENaCγ
gene.BMI kg/m−2 FEV1 %
pred.
Lung
transplant
IV antibiotic
courses/year
Bronchial
colonization
19.7 76 No 0 P. aeruginosa
25.6 74 No 1 P. aeruginosa
15.0 18 Awaiting 12 B. cepacia
in one second, BMI: body mass index.
Table 4
Nasal PD measurements and sweat test in CF patients bearing a missense mutation in ENaCβ or ENaCγ
Patient
number
CFTR mutations ENaC
mutations
Basal NPD
(mV)
Δamil
(mV)
Δ0Cl−/amil
(mV)
Δ(iso/0Cl−)
(mV)
Cl− sweat
mmol/L
1 F508del: F508del p.Gly589Ser −61 56 0 −5 114
2 F508del: F508del p.Leu481Gln:
p.Val546Ileu
−51 22 1 1 115
3 F508del: R347P p.Thr313Met Not done 64
NPD: nasal potential difference; amil: amiloride.
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Screening of theENaCβgene by dHPLCanddirect sequencing
revealed two different amino acids changes (p.Thr313Met
c.938CNT in exon 6; p.Gly589Ser c.1765GNA in exon 13), two
silent polymorphisms (p.Pro93Pro c.279CNT in exon 2; p.
Phe293Phe c.879CNT in exon 5) and three nucleotide changes
in the noncoding region (c.911+41CNT in two cases; c.1482-
23GNA, c.1602-14GNA). The silent polymorphism p.Phe293Phe
was observed in three patients (3/56; 5.4%) (1 heterozygote in
group 1, 1 homozygote and 1 heterozygote in group 2) (NS). The
common polymorphism p.Pro93Pro (c.279CNT in exon 2) was
identified at the heterozygous state in 28 patients (28/56; 50%) (18
in group 1 and 10 in group 2) and at the homozygous state in 11
patients (11/56; 19.6%) (7 in group 1 and 4 in group 2) (NS).
The two amino acid changes resulting from missense
mutations in the ENaCβ gene were found in two unrelated
CF patients (1 in group 1 and 1 in group 2). The p.Gly589Ser
variant was found in a CF patient homozygote for the
Phe508del mutation presenting a mild pulmonary phenotype
(FEV1% 76%, no intravenous antibiotic course despite
Pseudomonas aeruginosa chronic bronchial colonization).
The new variant p.Thr313Met was present in a CF patient
aged 27 years old, with mild CFTR genotype (Phe508del:
R347P) but presenting a severe lung disease with Burkhol-
deria cepacia colonization (FEV1 18%; continuous intrave-
nous antibiotic treatment awaiting lung transplantation)
(Table 3).
Recent studies of normal and alternative splicing
suggest that the deleterious effects of nucleotide substitu-
tions might be splicing related when they are located in
exonic splicing enhancers (ESEs) [21,24]. To test whether
these ENaCβ substitutions disrupt ESE sites, we analysed
wild type and mutant sequences with the ESE finder
program. The substitution p.Phe293Phe (c.879CNT) (also
named rs250563) did not change the score of an ESE
element. However, the common substitution p.Pro93Pro
(c.279CNT) affects the site of binding of SRp40 (loss of a
score of 2.9).
3.2. Screening of the ENaCγ gene
Screening of the ENaCγ gene by dHPLC and direct
sequencing revealed two amino acid changes (p.Leu481Gln
c.1442TNA in exon 12; p. Val546Ile c.1636GNA in exon 13),five silent polymorphisms (p.Tyr129Tyr (c.387TNC in exon
3); p.Ileu158Ileu (c.474TNC in exon 3); p.Gly183Gly
(c.549CNT in exon 3); p.Ser212Ser (c.636CNT in exon 4);
p.Leu649Leu c.1947 CNG in exon 13) and two intronic
sequence variations (c.1371+29TNC; c.1432-7GNA). None
of these intronic nucleotide changes altered the consensus
splice sites, suggesting that they are common polymorph-
isms rather than disease-causing mutations. The common
polymorphisms p.Tyr129Tyr and p.Ileu158Ileu (also named
rs4365290 and rs5735, respectively) were observed in 25
and 24 patients, respectively (25/56, 44.6%; 24/56; 42.8%)
(NS) at the heterozygous state. The distribution of these
polymorphisms was slightly different in the two groups (12/
38 31% in group 1; 12/18 in group 2, 66% for p.Ileu148Ileu)
(p=0.025). In the ensembl database (www.ensembl.org),
these variants were observed at the homozygous state in 8%
and at the heterozygous state in 54% of normal individuals.
The common polymorphism p.Leu649Leu (also named
rs5723) was identified in 20 patients (20/56; 34%) and was
in perfect linkage with the two intronic sequence variations
c.1371+29TNC and c.1432-7GNA. The distribution of this
silent variant was also similar in the two groups 1 and 2 (15/
38 39%; 6/18 33%, respectively) (NS). In group 1 10/38
(26%) patients presented TG haplotype (T at Ileu158 and G
at Leu 549) and 3/18 (16%) in group 2 (NS). In a previous
study, this silent variant was detected at the homozygous
state in 6% and at the heterozygous state in 34% of normal
individuals [25]. The common polymorphism p.Ser212Ser
(named also rs16977041) was observed in three unrelated
CF patients (3 in group 1, 7.9% and 1 in group 2, 5.9%)
(NS). In the ensembl database, the variant p.Ser212Ser was
identified at the homozygous state in 5% and at the
heterozygous state in 24% of normal individuals. The
polymorphism p.Gly183Gly was identified at the hetero-
zygous state in 9 individuals (9/56; 16%). The distribution of
this silent variant was similar in the two groups (5/38, 13%
and 4/18, 22%) (NS).
To test whether these ENaCγ substitutions disrupt ESE
sites, we analysed wild type and mutant sequences with the
ESEfinder program. The substitution p.Leu649Leu affected
the site of binding of SC35 (loss of a score of 3), SF2 (loss of a
score of 2.5) and reduced the score for SRp40 (score 3.4N2.8).
The silent variant p.Ser212Ser also affected the site of binding
for SF2/ASF (loss of a score of 2.2), SRp40 (loss of a score
2.5), but increased the score for SC35 (score 2.5N3.2).
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novel variant p.Leu481Gln were found in the same CF patient.
This genotype had not previously been found in normal
subjects and in more than 60 patients with bronchiectasis (data
not shown). This patient, aged of 24 years, was homozygous
for the common CF mutation p.Phe508del and presented an
unexpectedly mild pulmonary phenotype (Table 3). FEV1%
was 74% pred. and he had received only one intravenous
antibiotic course a year. His nasal PD measurements were
those expected in CF without any peculiarity: a high nasal PD
(−51 mV), a large PD inhibition in response to amiloride
(−22 mV,Δamil=29 mV) and an absence of response to low-
chloride solution (−21 mV, Δ0Cl−/amil=±1 mV) and
isoproterenol (−20 mV, Δiso/0Cl−=+1 mV) (Table 4).
In total, we only found 3 patients out of 56 carrying at
least one missense mutation in ENaCβ or ENaCγ. The
variant p.Thr313Met has been identified in a CF patient with
mild genotype and severe lung phenotype suggesting that
they can act in increasing ENaC activity. On the contrary, the
variants p.Gly589Ser, p.Leu481Gln and p.Val546Ileu have
been identified in CF patients with severe genotype and mild
lung phenotype suggesting that they might decrease ENaC
activity.
4. Discussion
Nonsense and frameshift mutations in the ENaC beta and
gamma genes produce truncated non-functional proteins and
therefore are sufficiently damaging to cause a loss of
function with salt wasting and low blood pressure (PHA type
I). Moreover, several missense mutations located in domains
participating in ENaC trafficking decreasing ENaC traffick-
ing to the cell surface, also cause PHA type I. Besides the
mutations causing a loss of function, it has been shown that
truncation of the C terminus of the beta and gamma subunits
by frameshift mutations caused Liddle's syndrome [26].
More recently, missense mutations located in a conserved PY
motif (PPPXYXXL codon 611 to 623) in the C-terminus of
beta ENaC were identified in some families [9,27] and
reproduced the defect observed in Liddle's syndrome. These
mutations cause a gain of function, and very often an
increased ENaC surface expression. If a nucleotide substitu-
tion mildly affects ENaC surface expression, it could modify
sodium hyperabsorption due to a CFTR defect and modulate
the severity of lung disease.
The 56 CF adult patients enrolled within this study have
been selected from a set of more than 400 patients on the
basis of the discordance between their CFTR genotype and
their lung phenotype.
Among the 4 different missense variants identified in our
CF patients, two were novel amino acid changes. These
variants have not previously been found in normal subjects
or in patients with bronchiectasis. Three variants are located
in conserved residues (Thr313, Gly589 in ENaCβ and Leu
481 in ENaCγ). The p.Gly589Ser variant was found in a CF
patient homozygote for the Phe508del CFTR mutationpresenting a mild pulmonary phenotype. The p.Leu481Gln
and p.Val546Ile variants were found in a CF patient
homozygote for the Phe508del mutation presenting a similar
mild phenotype. These data suggest that these variants could
decrease the function of ENaC and modulate the severity of
CF lung disease in CF patients bearing two severe mutations
in limiting the hyperabsorption of sodium. However, their
nasal PD measurements, i.e. basal nasal PD and response to
amiloride, did not support a functional effect of these
variants on Na+ transport, at least in nasal epithelium.
Moreover, the substitution of serine for glycine (p.G589S in
ENaCβ) has been previously described in 1% of blood
donors and normotensive males and 2% of hypertensive
individuals [28–30] and it has been shown that this variant
had no detectable functional consequences on ENaC activity,
at least when expressed in Xenopus oocytes [30]. In contrast,
no amino acid change in ENaCγ was found in CF patients
with a mild genotype and a severe lung disease.
Nevertheless, the CF patient bearing the p.Thr313Met
variant in ENaCβ presented a severe lung disease with B.
cepacia colonization. These data can suggest that this variant
could increase the function of ENaC and increase the
hyperabsorption of sodium in absence of functional CFTR.
Unfortunately, no PD measurement was performed in this
CF patient, because she was treated with oxygen.
In a recent study it has been shown that the ENaCγ
haplotype (rs5735–rs5723; Ileu158Ileu–Leu649Leu) was
underrepresented among CF siblings suggesting that a
significant proportion of CF offspring who randomly
inherited the ENaCγ TG haplotype from their parents did
not survive to an age that allowed them to match the
recruitment criteria for this study [31]. In contrast to this
previous study, we found a non-significant excess of the
ENaCγ haplotype TG (26%) in patients with severe
genotype and mild phenotype compared to CF patients
with mild genotype and severe phenotype (15%).
In conclusion, the frequency of missense variants is
similar in the two groups with discordant phenotype
according to the CFTR genotype and the function of ENaC
in the nasal epithelia of these CF patients bearing a missense
variant did not support the fact that these variants were
functional at least in nasal epithelium. Although the
significance of these findings at the functional level requires
further investigation, all these data suggest that genetic
variants in ENaCβ and γ do not modulate the disease
severity in the majority of CF patients.
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